医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Presbia Announces the Start of Commercialization of the Presbia Flexivue Micolens™ in Australia

2015年04月21日 PM09:00
このエントリーをはてなブックマークに追加


 

DUBLIN

Presbia PLC (NASDAQ: LENS), an ophthalmic device company that has developed and is currently marketing Presbia Flexivue Microlens™, a proprietary optical lens implant for treating presbyopia, announced today that it has commenced commercialization of its Microlens in Australia and has appointed The Media Planning Agency, an Australian-based firm, to develop and manage the strategic marketing campaign objectives in both traditional and new media. Presbia is expanding its advertising and marketing activities to further reach and engage customers, strengthening Presbia’s brand and position across the continent.

“Formalizing the relationship with The Media Planning Agency will broaden our outreach in Australia and provide patients with our tissue-sparing procedure as a treatment option for near-vision loss,” said Todd Cooper, President and CEO of Presbia. “Enlarging our footprint in this geographical area is an important aspect of our international commercialization and growth strategy.”

Presbia Flexivue Microlens™ and Flexivue Microlens Inserter are included in the Australian Register of Therapeutic Goods (ARTG).

Forward-Looking Statements

Information provided and statements contained in this press release that are not purely historical are forward-looking statements. Such forward-looking statements only speak as of the date of this press release and Presbia assumes no obligation to update the information included in this press release. Statements made in this press release that are forward-looking in nature may involve risks and uncertainties. Accordingly, readers are cautioned that any such forward-looking statements are not guarantees and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Although Presbia believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Unless otherwise required by law, Presbia also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made in this press release.

About Presbia

Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that has developed and is currently marketing the presbyopia-correcting Presbia Flexivue Microlens™, a miniature lens that is implanted in a corneal pocket created by a femtosecond laser. The Presbia Flexivue Microlens™ has received a CE mark for the European Economic Area, allowing the lens to be marketed in over 30 countries across Europe. A staged pivotal U.S. clinical trial for the Presbia Flexivue Microlens™ commenced in 2014.

CONTACT

Presbia PLC
Monica Yamada, 323-860-4903
monica@presbia.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表